Published in Nat Rev Nephrol on April 23, 2013
Inflammation, oxidative stress and renin angiotensin system in atherosclerosis. World J Biol Chem (2015) 0.99
An integrated approach to defining genetic and environmental determinants for major clinical outcomes involving vitamin D. Mol Diagn Ther (2014) 0.91
Vitamin D and neurocognitive function. Clin Interv Aging (2014) 0.87
Ischemic heart disease in women: a focus on risk factors. Trends Cardiovasc Med (2014) 0.87
Vitamin D in renal transplantation - from biological mechanisms to clinical benefits. Am J Transplant (2014) 0.86
Assessment of low vitamin D among Saudi Arabians. Did we overshoot the runway? Saudi Med J (2014) 0.84
Relationship between vitamin D deficiency and cardiovascular disease. World J Cardiol (2013) 0.83
Relationship among 25-hydroxyvitamin D concentrations, insulin action, and cardiovascular disease risk in patients with essential hypertension. Am J Hypertens (2014) 0.80
Vitamin D & its analogues in type 2 diabetic nephropathy: a systematic review. J Diabetes Metab Disord (2015) 0.78
Acute Phase Response: Implication in ST-segment Elevation Myocardial Infarction. Open Biochem J (2014) 0.78
Is the Association between Vitamin D and Cardiovascular Disease Risk Confounded by Obesity? Evidence from the Andhra Pradesh Children and Parents Study (APCAPS). PLoS One (2015) 0.77
Effect of paricalcitol and enalapril on renal inflammation/oxidative stress in atherosclerosis. World J Biol Chem (2015) 0.75
The systemic nature of CKD. Nat Rev Nephrol (2017) 0.75
A randomized control trial to assess the impact of vitamin D supplementation compared to placebo on vascular stiffness in chronic kidney disease patients. BMC Cardiovasc Disord (2014) 0.75
Vitamin D deficiency. N Engl J Med (2007) 59.34
Atherosclerosis--an inflammatory disease. N Engl J Med (1999) 59.28
Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab (2011) 23.10
Vitamin D deficiency and risk of cardiovascular disease. Circulation (2008) 13.39
KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl (2009) 12.66
1,25-Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system. J Clin Invest (2002) 9.50
Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med (2008) 9.19
25-hydroxyvitamin D and risk of myocardial infarction in men: a prospective study. Arch Intern Med (2008) 8.03
Hypovitaminosis D prevalence and determinants among African American and white women of reproductive age: third National Health and Nutrition Examination Survey, 1988-1994. Am J Clin Nutr (2002) 7.34
FGF23 induces left ventricular hypertrophy. J Clin Invest (2011) 7.22
Plasma 25-hydroxyvitamin D levels and risk of incident hypertension. Hypertension (2007) 6.99
Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Proc Natl Acad Sci U S A (2001) 6.70
Vitamin D levels and early mortality among incident hemodialysis patients. Kidney Int (2007) 6.35
Fracture prevention with vitamin D supplementation: a meta-analysis of randomized controlled trials. JAMA (2005) 5.95
Systematic review: Vitamin D and cardiometabolic outcomes. Ann Intern Med (2010) 5.36
Vitamin D therapy and cardiac structure and function in patients with chronic kidney disease: the PRIMO randomized controlled trial. JAMA (2012) 5.27
Phosphate regulation of vascular smooth muscle cell calcification. Circ Res (2000) 5.18
Prevalence of vitamin D deficiency among healthy adolescents. Arch Pediatr Adolesc Med (2004) 4.95
The associations of fibroblast growth factor 23 and uncarboxylated matrix Gla protein with mortality in coronary artery disease: the Heart and Soul Study. Ann Intern Med (2010) 4.89
Vitamin D supplementation improves cytokine profiles in patients with congestive heart failure: a double-blind, randomized, placebo-controlled trial. Am J Clin Nutr (2006) 4.74
Arterial calcifications, arterial stiffness, and cardiovascular risk in end-stage renal disease. Hypertension (2001) 4.70
Relation of vitamin D deficiency to cardiovascular risk factors, disease status, and incident events in a general healthcare population. Am J Cardiol (2010) 4.27
Baseline serum 25-hydroxy vitamin d is predictive of future glycemic status and insulin resistance: the Medical Research Council Ely Prospective Study 1990-2000. Diabetes (2008) 4.11
Cardiac hypertrophy in vitamin D receptor knockout mice: role of the systemic and cardiac renin-angiotensin systems. Am J Physiol Endocrinol Metab (2004) 3.75
FGF-23 associates with death, cardiovascular events, and initiation of chronic dialysis. J Am Soc Nephrol (2011) 3.52
Mineral metabolism and arterial functions in end-stage renal disease: potential role of 25-hydroxyvitamin D deficiency. J Am Soc Nephrol (2007) 3.41
Fibroblast growth factor 23 is a counter-regulatory phosphaturic hormone for vitamin D. J Am Soc Nephrol (2006) 3.36
FGFs, heparan sulfate and FGFRs: complex interactions essential for development. Bioessays (2000) 3.31
Serum 25-hydroxyvitamin D concentration and subsequent risk of type 2 diabetes. Diabetes Care (2007) 3.10
Serum 25-hydroxyvitamin D, ethnicity, and blood pressure in the Third National Health and Nutrition Examination Survey. Am J Hypertens (2007) 3.10
Pharmacokinetics of vitamin D toxicity. Am J Clin Nutr (2008) 3.09
Leucocyte-endothelial interactions and regulation of leucocyte migration. Lancet (1994) 2.96
The effect of micronutrient supplementation on quality-of-life and left ventricular function in elderly patients with chronic heart failure. Eur Heart J (2005) 2.92
Vitamin D improves endothelial function in patients with Type 2 diabetes mellitus and low vitamin D levels. Diabet Med (2008) 2.85
Plasma 25-hydroxyvitamin D levels and risk of incident hypertension among young women. Hypertension (2008) 2.81
Vitamin D insufficiency among free-living healthy young adults. Am J Med (2002) 2.80
Vitamin D supplementation for prevention of mortality in adults. Cochrane Database Syst Rev (2011) 2.72
Calcium-independent and 1,25(OH)2D3-dependent regulation of the renin-angiotensin system in 1alpha-hydroxylase knockout mice. Kidney Int (2008) 2.59
The VITamin D and OmegA-3 TriaL (VITAL): rationale and design of a large randomized controlled trial of vitamin D and marine omega-3 fatty acid supplements for the primary prevention of cancer and cardiovascular disease. Contemp Clin Trials (2011) 2.59
Extra-renal 25-hydroxyvitamin D3-1alpha-hydroxylase in human health and disease. J Steroid Biochem Mol Biol (2007) 2.42
Vitamin D reduces left atrial volume in patients with left ventricular hypertrophy and chronic kidney disease. Am Heart J (2012) 2.42
Vitamin D and type 2 diabetes: a systematic review. Eur J Clin Nutr (2011) 2.38
Vitamin D levels and patient outcome in chronic kidney disease. Kidney Int (2008) 2.38
25-Hydroxyvitamin D deficiency is associated with inflammation-linked vascular endothelial dysfunction in middle-aged and older adults. Hypertension (2010) 2.33
Effect of vitamin D deficiency and replacement on endothelial function in asymptomatic subjects. J Clin Endocrinol Metab (2009) 2.28
Vitamin D and cardiovascular disease: systematic review and meta-analysis of prospective studies. Prev Med (2010) 2.27
Vitamin D inhibits monocyte/macrophage proinflammatory cytokine production by targeting MAPK phosphatase-1. J Immunol (2012) 2.27
The effect of different doses of vitamin D(3) on markers of vascular health in patients with type 2 diabetes: a randomised controlled trial. Diabetologia (2010) 2.26
Activated vitamin D attenuates left ventricular abnormalities induced by dietary sodium in Dahl salt-sensitive animals. Proc Natl Acad Sci U S A (2007) 2.25
Tumor necrosis factor-alpha promotes in vitro calcification of vascular cells via the cAMP pathway. Circulation (2000) 2.22
Forging forward with 10 burning questions on FGF23 in kidney disease. J Am Soc Nephrol (2010) 2.20
Plasma cytokine parameters and mortality in patients with chronic heart failure. Circulation (2000) 2.18
Vitamin D deficiency and mortality risk in the general population: a meta-analysis of prospective cohort studies. Am J Clin Nutr (2011) 2.16
Differential effects of vitamin D receptor activators on vascular calcification in uremic rats. Kidney Int (2007) 2.15
Vitamin D and cardiovascular outcomes: a systematic review and meta-analysis. J Clin Endocrinol Metab (2011) 2.11
Tumor necrosis factor-alpha and tumor necrosis factor receptors in the failing human heart. Circulation (1996) 2.10
Vitamin D status and the risk of cardiovascular disease death. Am J Epidemiol (2009) 2.06
Synthesis of 1,25-dihydroxyvitamin D(3) by human endothelial cells is regulated by inflammatory cytokines: a novel autocrine determinant of vascular cell adhesion. J Am Soc Nephrol (2002) 2.02
Serum 25-hydroxyvitamin D status and cardiovascular outcomes in chronic peritoneal dialysis patients: a 3-y prospective cohort study. Am J Clin Nutr (2008) 1.95
Effect of vitamin D on blood pressure: a systematic review and meta-analysis. J Hypertens (2009) 1.95
Oral administration of an active form of vitamin D3 (calcitriol) decreases atherosclerosis in mice by inducing regulatory T cells and immature dendritic cells with tolerogenic functions. Arterioscler Thromb Vasc Biol (2010) 1.87
Vitamin D status and mortality risk in CKD: a meta-analysis of prospective studies. Am J Kidney Dis (2011) 1.83
Vitamin D supplementation and regulatory T cells in apparently healthy subjects: vitamin D treatment for autoimmune diseases? Isr Med Assoc J (2010) 1.82
Cardiomyocyte-specific deletion of the vitamin D receptor gene results in cardiac hypertrophy. Circulation (2011) 1.81
Adolescent girls in Maine are at risk for vitamin D insufficiency. J Am Diet Assoc (2005) 1.74
Vitamin D status is associated with arterial stiffness and vascular dysfunction in healthy humans. J Am Coll Cardiol (2011) 1.72
Vitamin D, race, and cardiovascular mortality: findings from a national US sample. Ann Fam Med (2010) 1.72
Calcium and 1 alpha,25-dihydroxyvitamin D3 target the TNF-alpha pathway to suppress experimental inflammatory bowel disease. Eur J Immunol (2005) 1.69
Plasma 25-hydroxyvitamin D and regulation of the renin-angiotensin system in humans. Hypertension (2010) 1.69
Vascular calcification: in vitro evidence for the role of inorganic phosphate. J Am Soc Nephrol (2003) 1.67
Intravenous calcitriol regresses myocardial hypertrophy in hemodialysis patients with secondary hyperparathyroidism. Am J Kidney Dis (1999) 1.63
Vitamin D supplementation in chronic kidney disease: a systematic review and meta-analysis of observational studies and randomized controlled trials. Clin J Am Soc Nephrol (2010) 1.63
Effects of vitamin D supplementation on blood pressure. South Med J (2010) 1.63
Vascular calcification and inorganic phosphate. Am J Kidney Dis (2001) 1.55
Role of vitamin D in blood pressure homeostasis. Am J Ther (2010) 1.54
Vitamin D receptor activators inhibit vascular smooth muscle cell mineralization induced by phosphate and TNF-α. Nephrol Dial Transplant (2012) 1.52
Vitamin D and mortality in older men and women. Clin Endocrinol (Oxf) (2009) 1.50
Normal serum vitamin D levels. N Engl J Med (2005) 1.46
Intravenous calcitriol therapy increases serum concentrations of fibroblast growth factor-23 in dialysis patients with secondary hyperparathyroidism. Nephron Clin Pract (2005) 1.46
Relationship of 25-hydroxyvitamin D with all-cause and cardiovascular disease mortality in older community-dwelling adults. Eur J Clin Nutr (2009) 1.42
Modulatory calcineurin-interacting proteins 1 and 2 function as calcineurin facilitators in vivo. Proc Natl Acad Sci U S A (2006) 1.40
Blood 25-hydroxyvitamin D concentration and hypertension: a meta-analysis. J Hypertens (2011) 1.32
Effects of cinacalcet and concurrent low-dose vitamin D on FGF23 levels in ESRD. Clin J Am Soc Nephrol (2009) 1.30
1-alpha,25-Dihydroxyvitamin D3 (1,25(OH)(2)D(3)) hampers the maturation of fully active immature dendritic cells from monocytes. Eur J Endocrinol (2001) 1.29
The role of 1,25-dihydroxyvitamin D in the mechanism of acquired vitamin D deficiency. Clin Endocrinol (Oxf) (1992) 1.28
25-Hydroxyvitamin D levels and the risk of stroke: a prospective study and meta-analysis. Stroke (2012) 1.27
Vitamin D affects survival independently of vascular calcification in chronic kidney disease. Clin J Am Soc Nephrol (2009) 1.26
Vitamin D deficiency is associated with depletion of circulating endothelial progenitor cells and endothelial dysfunction in patients with type 2 diabetes. J Clin Endocrinol Metab (2011) 1.25
Addressing the musculoskeletal components of fracture risk with calcium and vitamin D: a review of the evidence. Calcif Tissue Int (2006) 1.24
Disruption of nuclear vitamin D receptor gene causes enhanced thrombogenicity in mice. J Biol Chem (2004) 1.24
Vitamin D, cardiovascular disease and mortality. Clin Endocrinol (Oxf) (2011) 1.24
Fibroblast growth factor 23 and disordered vitamin D metabolism in chronic kidney disease: updating the "trade-off" hypothesis. Clin J Am Soc Nephrol (2010) 1.21
Vitamin D levels and mortality in type 2 diabetes. Diabetes Care (2010) 1.21
Basic and clinical aspects of parathyroid hyperplasia in chronic kidney disease. Kidney Int Suppl (2006) 1.16
Improvement of vitamin D status resulted in amelioration of biomarkers of systemic inflammation in the subjects with type 2 diabetes. Diabetes Metab Res Rev (2012) 1.10
Calcitriol regresses cardiac hypertrophy and QT dispersion in secondary hyperparathyroidism on hemodialysis. Nephron Clin Pract (2005) 1.10
Anti-inflammatory effect of 1alpha,25-dihydroxyvitamin D(3) in human coronary arterial endothelial cells: Implication for the treatment of Kawasaki disease. J Steroid Biochem Mol Biol (2008) 1.10
Secondary hyperparathyroidism: pathophysiology and treatment. J Am Board Fam Med (2009) 1.10
A bimodal association of vitamin D levels and vascular disease in children on dialysis. J Am Soc Nephrol (2008) 1.09
Independent associations of serum concentrations of 25-hydroxyvitamin D and parathyroid hormone with blood pressure among US adults. J Hypertens (2010) 1.08
New equations to estimate GFR in children with CKD. J Am Soc Nephrol (2009) 11.48
Bioavailable vitamin D is more tightly linked to mineral metabolism than total vitamin D in incident hemodialysis patients. Kidney Int (2012) 2.74
Chronic kidney disease, hypovitaminosis D, and mortality in the United States. Kidney Int (2009) 2.52
Obesity and obesity-initiated metabolic syndrome: mechanistic links to chronic kidney disease. Clin J Am Soc Nephrol (2007) 2.25
Association between long-term blood pressure variability and mortality among incident hemodialysis patients. Am J Kidney Dis (2008) 1.79
Prevalence and outcomes of antimicrobial treatment for Staphylococcus aureus bacteremia in outpatients with ESRD. J Am Soc Nephrol (2012) 1.77
Association of eGFR-Related Loci Identified by GWAS with Incident CKD and ESRD. PLoS Genet (2011) 1.68
Modulation of melanocortin signaling ameliorates uremic cachexia. Kidney Int (2008) 1.60
Melanocortin antagonism ameliorates muscle wasting and inflammation in chronic kidney disease. Am J Physiol Renal Physiol (2012) 1.58
No difference in bleeding risk between subcutaneous enoxaparin and heparin for thromboprophylaxis in end-stage renal disease. Kidney Int (2013) 1.45
Diets and enteral supplements for improving outcomes in chronic kidney disease. Nat Rev Nephrol (2011) 1.42
Wasting in chronic kidney disease. J Cachexia Sarcopenia Muscle (2011) 1.39
Metabolic abnormalities, cardiovascular disease risk factors, and GFR decline in children with chronic kidney disease. Clin J Am Soc Nephrol (2011) 1.34
Role of leptin and melanocortin signaling in uremia-associated cachexia. J Clin Invest (2005) 1.30
Inflammation and cachexia in chronic kidney disease. Pediatr Nephrol (2010) 1.20
Posterior reversible encephalopathy syndrome in children with kidney diseases. Pediatr Nephrol (2011) 1.18
Vitamin D therapy in chronic kidney disease and end stage renal disease. Clin J Am Soc Nephrol (2011) 1.09
Conversion of peripheral blood NK cells to a decidual NK-like phenotype by a cocktail of defined factors. J Immunol (2013) 1.07
Peripheral administration of the melanocortin-4 receptor antagonist NBI-12i ameliorates uremia-associated cachexia in mice. J Am Soc Nephrol (2007) 1.02
Quantifying a rare disease in administrative data: the example of calciphylaxis. J Gen Intern Med (2014) 1.01
Vitamin D deficiency and toxicity in chronic kidney disease: in search of the therapeutic window. Pediatr Nephrol (2010) 1.00
Vitamin D and hypertension: an update and review. Curr Opin Nephrol Hypertens (2012) 0.96
Hypertension during pregnancy: a disorder begging for pathophysiological support. Hypertension (2005) 0.95
Protein energy wasting in children with chronic kidney disease. Pediatr Nephrol (2014) 0.95
Plasma concentrations of soluble endoglin versus standard evaluation in patients with suspected preeclampsia. PLoS One (2012) 0.94
Carbamylation of serum albumin and erythropoietin resistance in end stage kidney disease. Clin J Am Soc Nephrol (2013) 0.92
Nutrition and growth in children with chronic kidney disease. Nat Rev Nephrol (2011) 0.92
Association of hemoglobin variability and mortality among contemporary incident hemodialysis patients. Clin J Am Soc Nephrol (2008) 0.92
Vitamin D status of newborns in New Zealand. Br J Nutr (2010) 0.91
Case records of the Massachusetts General Hospital. Case 38-2005. A 29-year-old pregnant woman with the nephrotic syndrome and hypertension. N Engl J Med (2005) 0.90
Does vitamin D modulate blood pressure? Curr Opin Nephrol Hypertens (2013) 0.89
Phosphate homeostasis in CKD: report of a scientific symposium sponsored by the National Kidney Foundation. Am J Kidney Dis (2013) 0.88
Acute kidney injury in children: the dawn of a new era. Pediatr Nephrol (2008) 0.87
A pegylated leptin antagonist ameliorates CKD-associated cachexia in mice. J Am Soc Nephrol (2013) 0.85
Ghrelin and its analogues as therapeutic agents for anorexia and cachexia in end-stage renal disease. Kidney Int (2009) 0.84
Nutrition in infants and very young children with chronic kidney disease. Pediatr Nephrol (2011) 0.84
Growth in children with chronic kidney disease: role of nutrition, growth hormone, dialysis, and steroids. Curr Opin Pediatr (2014) 0.83
Ghrelin in chronic kidney disease. Int J Pept (2010) 0.81
Ghrelin and leptin pathophysiology in chronic kidney disease. Pediatr Nephrol (2012) 0.81
Placental histomorphometry in gestational diabetes mellitus: the relationship between subsequent type 2 diabetes mellitus and race/ethnicity. Am J Clin Pathol (2014) 0.81
Is obesity a risk factor for chronic kidney disease in children? Pediatr Nephrol (2012) 0.80
MicroRNAs: a new therapeutic frontier for muscle wasting in chronic kidney disease. Kidney Int (2012) 0.78
Early markers of obesity-related renal injury in childhood. Pediatr Nephrol (2014) 0.77
8th International Symposium on Growth and Nutrition in Children with Chronic Renal Disease: 28-30 May 2009, Oviedo, Asturias, Spain. Pediatr Nephrol (2010) 0.77
Chronic kidney disease in children: state of the art. Pediatr Nephrol (2006) 0.77
Evaluation and management of hydronephrosis in the neonate. Curr Opin Pediatr (2016) 0.75
Shining light on vitamin D trials in chronic kidney disease. Kidney Int (2013) 0.75
Pediatrics: Masked hypertension: a risk factor in children with CKD. Nat Rev Nephrol (2010) 0.75
Pediatrics: blood pressure target for renoprotection in children. Nat Rev Nephrol (2010) 0.75
Serum myostatin in patients on maintenance haemodialysis: a useful biomarker of muscle wasting?. Clin Endocrinol (Oxf) (2011) 0.75
Recent advances in chronic dialysis and renal transplantation in children. Pediatr Nephrol (2009) 0.75
The impact of inflammation on bone mass in children. Pediatr Nephrol (2011) 0.75
Teaching articles: a new goal of the journal. Pediatr Nephrol (2006) 0.75
Nephrotic syndrome in an 18-year-old boy with congenital myelomeningocele: questions. Pediatr Nephrol (2012) 0.75